Cargando…
Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis
This study aimed to estimate the incidence of central nervous system (CNS) metastases in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) treated with trastuzumab. Studies were identified through a literature search of electronic databases. Random...
Autores principales: | Bai, Xue, Lin, Xue, Song, Jin, Chang, Jia-han, Han, Li-li, Fan, Cibo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculdade de Medicina / USP
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341052/ https://www.ncbi.nlm.nih.gov/pubmed/34406268 http://dx.doi.org/10.6061/clinics/2021/e2653 |
Ejemplares similares
-
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
por: Clayton, A J, et al.
Publicado: (2004) -
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
por: Swain, S. M., et al.
Publicado: (2014) -
Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer
por: Danese, Mark D., et al.
Publicado: (2012) -
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019) -
Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial
por: Xie, Xiao-Feng, et al.
Publicado: (2022)